vs
Riley Exploration Permian, Inc.（REPX）与Vericel Corp（VCEL）财务数据对比。点击上方公司名可切换其他公司
Riley Exploration Permian, Inc.的季度营收约是Vericel Corp的1.2倍（$113.9M vs $92.9M），Vericel Corp净利率更高（25.0% vs -61.8%，领先86.9%），Vericel Corp同比增速更快（23.3% vs 11.2%），Riley Exploration Permian, Inc.自由现金流更多（$24.6M vs $12.8M），过去两年Vericel Corp的营收复合增速更高（34.6% vs 3.9%）
Riley Exploration Permian, Inc.是一家独立能源企业，专注于美国得克萨斯州与新墨西哥州境内的二叠纪盆地，开展原油、天然气及天然气凝析液的勘探、开发与生产业务，主打低成本陆上储备开发，为北美市场供应稳定能源产品。
Vericel Corp是一家美国上市生物制药企业，前身为1989年在密歇根州安娜堡成立的Aastrom Bio，2014年10月正式更为现名，专注于生物制药相关领域的研发与商业化运营。
REPX vs VCEL — 直观对比
营收规模更大
REPX
是对方的1.2倍
$92.9M
营收增速更快
VCEL
高出12.1%
11.2%
净利率更高
VCEL
高出86.9%
-61.8%
自由现金流更多
REPX
多$11.7M
$12.8M
两年增速更快
VCEL
近两年复合增速
3.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $113.9M | $92.9M |
| 净利润 | $-70.4M | $23.2M |
| 毛利率 | — | 78.7% |
| 营业利润率 | 38.3% | 24.1% |
| 净利率 | -61.8% | 25.0% |
| 营收同比 | 11.2% | 23.3% |
| 净利润同比 | — | 17.3% |
| 每股收益（稀释后） | $-3.38 | $0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收REPXVCEL
| Q1 26 | $113.9M | — | ||
| Q4 25 | $97.3M | $92.9M | ||
| Q3 25 | $106.9M | $67.5M | ||
| Q2 25 | $85.4M | $63.2M | ||
| Q1 25 | $102.5M | $52.6M | ||
| Q4 24 | $102.7M | $75.4M | ||
| Q3 24 | $102.3M | $57.9M | ||
| Q2 24 | $105.4M | $52.7M |
净利润REPXVCEL
| Q1 26 | $-70.4M | — | ||
| Q4 25 | — | $23.2M | ||
| Q3 25 | $16.3M | $5.1M | ||
| Q2 25 | $30.5M | $-553.0K | ||
| Q1 25 | $28.6M | $-11.2M | ||
| Q4 24 | — | $19.8M | ||
| Q3 24 | $25.7M | $-901.0K | ||
| Q2 24 | $33.5M | $-4.7M |
毛利率REPXVCEL
| Q1 26 | — | — | ||
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% |
营业利润率REPXVCEL
| Q1 26 | 38.3% | — | ||
| Q4 25 | 26.9% | 24.1% | ||
| Q3 25 | 27.0% | 5.1% | ||
| Q2 25 | 33.7% | -3.2% | ||
| Q1 25 | 48.3% | -24.3% | ||
| Q4 24 | 31.2% | 24.5% | ||
| Q3 24 | 17.1% | -4.3% | ||
| Q2 24 | 50.9% | -11.5% |
净利率REPXVCEL
| Q1 26 | -61.8% | — | ||
| Q4 25 | — | 25.0% | ||
| Q3 25 | 15.3% | 7.5% | ||
| Q2 25 | 35.7% | -0.9% | ||
| Q1 25 | 27.9% | -21.4% | ||
| Q4 24 | — | 26.3% | ||
| Q3 24 | 25.1% | -1.6% | ||
| Q2 24 | 31.8% | -8.9% |
每股收益（稀释后）REPXVCEL
| Q1 26 | $-3.38 | — | ||
| Q4 25 | $4.02 | $0.46 | ||
| Q3 25 | $0.77 | $0.10 | ||
| Q2 25 | $1.44 | $-0.01 | ||
| Q1 25 | $1.36 | $-0.23 | ||
| Q4 24 | $0.52 | $0.40 | ||
| Q3 24 | $1.21 | $-0.02 | ||
| Q2 24 | $1.59 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $137.5M |
| 总债务越低越好 | $240.7M | — |
| 股东权益账面价值 | $553.4M | $354.6M |
| 总资产 | $1.2B | $488.0M |
| 负债/权益比越低杠杆越低 | 0.43× | — |
8季度趋势，按日历期对齐
现金及短期投资REPXVCEL
| Q1 26 | — | — | ||
| Q4 25 | — | $137.5M | ||
| Q3 25 | — | $135.4M | ||
| Q2 25 | — | $116.9M | ||
| Q1 25 | — | $112.9M | ||
| Q4 24 | — | $116.2M | ||
| Q3 24 | — | $101.7M | ||
| Q2 24 | — | $102.5M |
总债务REPXVCEL
| Q1 26 | $240.7M | — | ||
| Q4 25 | $247.9M | — | ||
| Q3 25 | $367.0M | — | ||
| Q2 25 | $275.2M | — | ||
| Q1 25 | $249.3M | — | ||
| Q4 24 | $269.5M | — | ||
| Q3 24 | $288.6M | — | ||
| Q2 24 | $322.7M | — |
股东权益REPXVCEL
| Q1 26 | $553.4M | — | ||
| Q4 25 | $634.2M | $354.6M | ||
| Q3 25 | $566.5M | $321.9M | ||
| Q2 25 | $556.9M | $306.8M | ||
| Q1 25 | $532.4M | $295.5M | ||
| Q4 24 | $510.6M | $292.0M | ||
| Q3 24 | $507.4M | $257.5M | ||
| Q2 24 | $489.0M | $243.0M |
总资产REPXVCEL
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $488.0M | ||
| Q3 25 | $1.2B | $453.3M | ||
| Q2 25 | $1.0B | $435.6M | ||
| Q1 25 | $994.9M | $424.6M | ||
| Q4 24 | $993.5M | $432.7M | ||
| Q3 24 | $997.9M | $390.4M | ||
| Q2 24 | $1.0B | $376.8M |
负债/权益比REPXVCEL
| Q1 26 | 0.43× | — | ||
| Q4 25 | 0.39× | — | ||
| Q3 25 | 0.65× | — | ||
| Q2 25 | 0.49× | — | ||
| Q1 25 | 0.47× | — | ||
| Q4 24 | 0.53× | — | ||
| Q3 24 | 0.57× | — | ||
| Q2 24 | 0.66× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $47.2M | $15.0M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $12.8M |
| 自由现金流率自由现金流/营收 | 21.6% | 13.8% |
| 资本支出强度资本支出/营收 | 41.3% | 2.4% |
| 现金转化率经营现金流/净利润 | — | 0.65× |
| 过去12个月自由现金流最近4个季度 | — | $24.7M |
8季度趋势，按日历期对齐
经营现金流REPXVCEL
| Q1 26 | $47.2M | — | ||
| Q4 25 | $64.9M | $15.0M | ||
| Q3 25 | $63.6M | $22.1M | ||
| Q2 25 | $33.6M | $8.2M | ||
| Q1 25 | $50.4M | $6.6M | ||
| Q4 24 | $66.4M | $22.2M | ||
| Q3 24 | $72.1M | $10.2M | ||
| Q2 24 | $51.6M | $18.5M |
自由现金流REPXVCEL
| Q1 26 | $24.6M | — | ||
| Q4 25 | — | $12.8M | ||
| Q3 25 | — | $19.5M | ||
| Q2 25 | — | $81.0K | ||
| Q1 25 | — | $-7.6M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | — | $-9.2M | ||
| Q2 24 | — | $1.8M |
自由现金流率REPXVCEL
| Q1 26 | 21.6% | — | ||
| Q4 25 | — | 13.8% | ||
| Q3 25 | — | 28.8% | ||
| Q2 25 | — | 0.1% | ||
| Q1 25 | — | -14.5% | ||
| Q4 24 | — | 11.2% | ||
| Q3 24 | — | -15.9% | ||
| Q2 24 | — | 3.4% |
资本支出强度REPXVCEL
| Q1 26 | 41.3% | — | ||
| Q4 25 | — | 2.4% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 12.9% | ||
| Q1 25 | — | 27.0% | ||
| Q4 24 | — | 18.3% | ||
| Q3 24 | — | 33.5% | ||
| Q2 24 | — | 31.8% |
现金转化率REPXVCEL
| Q1 26 | — | — | ||
| Q4 25 | — | 0.65× | ||
| Q3 25 | 3.90× | 4.35× | ||
| Q2 25 | 1.10× | — | ||
| Q1 25 | 1.76× | — | ||
| Q4 24 | — | 1.12× | ||
| Q3 24 | 2.81× | — | ||
| Q2 24 | 1.54× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
REPX
暂无分部数据
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
